Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Calciphylaxis, also known as calcific uremic arteriolopathy (CUA), is a rare cutaneous microvascular disorder predominantly affecting patients with chronic kidney disease (CKD). It clinically manifests as rapidly progressive ischemic skin necrosis and ulceration, frequently complicated by severe secondary infections and even septic shock. Skin biopsy remains the gold standard for diagnosis, and the condition carries a one-year mortality rate as high as 80%. The lack of standardized clinical protocols limits the efficacy of conventional multidisciplinary approaches. Advances in regenerative medicine have recently offered new hope for this refractory disease. Human amniotic-derived mesenchymal stem cells (hAMSCs) have attracted considerable interest owing to their wide availability, lack of ethical issues, strong proliferative potential, and significant immunomodulatory and paracrine activities.
Since September 2018, with approval from the hospital ethics committee, our team has innovatively administered hAMSCs to treat over ten patients with calciphylaxis who showed poor response to conventional therapies. Procedural skin biopsy please see Fig 1. Here we systematically summarizes the clinical management protocol, including patient selection, multidisciplinary consultation, baseline assessment and wound care. Wound status is evaluated using the Bates-Jensen Wound Assessment Tool for Calcific Uremic Arteriolopathy（BWAT-CUA) scoring system, and pain intensity is measured using the Visual Analogue Scale (VAS).
For wound management, key assessment dimensions and grading criteria should guide the selection of appropriate dressings and treatment protocols (Fig 2).
The hAMSC product is manufactured by the hospital’s stem cell technology platform and has passed quality re-evaluation by the National Institutes for Food and Drug Control. The administration regimen is individualized and combined: intravenous infusion at a dose of 1.0×10⁶cells/kg and local intralesional injection at 2.0×10⁴cells/cm² of wound surface (Fig 3).
Acute adverse events are closely monitored throughout treatment, with established emergency response protocols. Preliminary long-term follow-up data suggest that hAMSC therapy is both safe and effective.
Based on these encouraging results, larger-scale, multicenter studies are warranted to validate the long-term efficacy and safety of hAMSC therapy. Future research should incorporate dynamic biomarker monitoring, optimize treatment protocols, strengthen multidisciplinary collaboration, and promote the standardized and precision-driven translation of stem cell therapies, ultimately establishing safer, more effective, and cost-efficient regenerative medicine approaches for patients.
